SEC Form 4 · accession 0001127602-17-011240
BIOCRYST PHARMACEUTICALS INC · BCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas R Staab II
Officer — Senior Vice President and CFO
Period of report
Mar 8, 2017
Accepted (ET)
Mar 10, 2017 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882796
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 8, 2017 | M | 6,500 | $3.78 | A | 123,813 | D | |
| Common StockF1 | Mar 8, 2017 | S | 3,250 | $8.20 | D | 120,563 | D | |
| Common StockF1 | Mar 8, 2017 | S | 3,250 | $8.65 | D | 117,313 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Emp. Stock Option (Right to Buy) | $3.78 | Mar 8, 2017 | M | 6,500 | D | Jul 1, 2012 | Jul 1, 2021 | Common Stock | 6,500 | 86,260 | D |
Explanation of responses
- F1This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2016.